Subject: Network Newswire Issues New Article on CBD and CIIX

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
Network Newswire Issues New Article on CBD and CIIX
Hot Stock to WatchHot Stock to Watch

Company: (OTCQB: CIIX)


Price: 1.03

Change (%): - 0.01 (0.96)

Volume: 7,528
CIIX Chart, Inc. (CIIX) Presents Obvious Upside

Archaeological research suggests that Cannabis Sativa, the source plant for cannabidiol (CBD) compounds, was one of the first agricultural crops planted by early man near the birth of agriculture some 10,000 to 12,000 years ago. The use of CBD for health benefits extends back several thousand years as well. CBD is one of more than 80 active cannabinoid chemicals in the Cannabis Sativa (marijuana) plant and is a part of the cannabis plant that does not produce euphoria or a “high”. Anecdotally, CBD has long been considered to have a broad range of medical benefits. Now, two major studies released in the last four months have scientifically validated the medicinal efficacy of CBD.

The New England Journal of Medicine just confirmed what thousands have attested to anecdotally for years ( The report shows that CBD dramatically reduced the number of convulsive seizures in children with a severe and often fatal epilepsy disorder. “The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with (a) placebo.” The results of the NEJM study follow a sweeping 400-page report released in January by the National Academies of Science, Engineering, and Medicine which covered more than 10,000 scientific studies on marijuana and medicine. The report’s conclusions that marijuana does have legitimate medical uses are supported by scientific studies that show cannabis and cannabinoids are effective at treating chronic pain and that cannabinoid substances were effective for treating chemotherapy-related nausea.

With medical efficacy questions resolved, smart money is now looking for avenues to profit from this explosive new medical market. The Hemp Business Journal ( recently projected that the CBD market will grow to a 2.1 billion dollar market in consumer sales by 2020; a 700% increase from 2016 in the U.S. alone. Globally, the growth could be even stronger.

Recently, (OTCQB: CIIX) has made several interesting announcements highlighting the worldwide growth potential from its investments and commitments in the global cannabis industry. The recent launch of what management identifies as the “world’s first Cannabidiol (CBD) health products online store in the Chinese Language (” is a significant milestone for the company and the 2+ billion Chinese speaking people it serves. The company also launched a Chinese language Yelp-style mobile application that contains a location-enabled database of recreational and medical marijuana dispensaries, as well as a platform to review and discuss various cannabis products. is about to make its mark in the global CBD market.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks